SomaReality Raises €3M+ for Eye-Tracking Cognitive Tech

Vienna-based deep tech innovator, SOMAREALITY, has successfully concluded an oversubscribed Series A funding round, securing more than €3 million. This significant capital injection was spearheaded by Catalyst Romania, marking its 13th deployment from its second fund, Catalyst Romania Fund II. The company's existing backers, including MT-Lab, RDY Ventures, Moondust Ventures, and Gateway Ventures, also reaffirmed their commitment through participation in this round.

The newly acquired funds are earmarked for strategic expansion over the next two years. SOMAREALITY plans to broaden its existing business-to-business (B2B) market reach, initiate new longitudinal studies focused on tracking and forecasting cognitive health and human performance, and embark on a brand extension into the consumer (B2C) sector. This multi-pronged approach signals an ambitious growth trajectory for the Austrian firm.

Founded in 2019, SOMAREALITY has developed proprietary algorithms that leverage eye-tracking data to provide real-time assessments of cognitive states. These insights encompass critical metrics such as cognitive load, attention levels, perception, fatigue, and overall performance. The company distinguishes itself by offering what it claims is the world's first comprehensive cognitive insights solution derived exclusively from eye tracking, presenting a non-invasive, real-time alternative to more cumbersome methods like electroencephalography (EEG), which often require controlled laboratory environments.

The underlying software is designed to be hardware-agnostic and operates on a transparent, white-box model. This architecture allows for the delivery of personalized cognitive insights within mere seconds of data acquisition. Available as both an on-premise integration and a web-based service, SOMAREALITY is also advancing towards on-chip deployment, enabling its technology to function directly on wearable glasses. Since its market entry in 2024 with the 'Cognitive Load' biomarker, the company has expanded its product suite to include measurements for conscious perception, attention, and fatigue onset.

The technology finds primary application in demanding sectors such as aviation, healthcare, and professional sports, alongside academic research. The company reports substantial commercial traction, having generated over €2 million in B2B revenue since its market launch in 2024. Furthermore, SOMAREALITY achieved a revenue doubling in 2025 compared to the preceding year, underscoring strong market adoption and product-market fit. This Series A funding follows a substantial seed round in November 2024, which itself was oversubscribed and closed at €2.6 million, bringing the total capital raised by the company to approximately €5.6 million.

The investment underscores the growing market interest in non-invasive, data-driven cognitive assessment tools. The global market for AI in healthcare, a sector where SOMAREALITY operates, is projected to grow significantly, driven by the demand for personalized medicine and enhanced diagnostic capabilities. The company's focus on eye-tracking technology positions it to capture a share of this expanding market, offering a scalable and accessible solution for understanding human cognitive states.